Safety, Efficacy and Pharmacokinetics of NNC-0156-0000-0009 in Previously Treated Children With Haemophilia B

Trial Profile

Safety, Efficacy and Pharmacokinetics of NNC-0156-0000-0009 in Previously Treated Children With Haemophilia B

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 26 Dec 2017

At a glance

  • Drugs Nonacog beta pegol (Primary)
  • Indications Haemophilia B
  • Focus Registrational; Therapeutic Use
  • Acronyms paradigm 5
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 12 Dec 2017 Results of an interim analysis (3.5 years data; As of April 1, 2016) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
    • 28 Nov 2017 Planned End Date changed from 30 Oct 2018 to 30 Nov 2023.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top